Cargando…

Comparative rates of upstaging and upgrading in Caucasian and Korean prostate cancer patients eligible for active surveillance

PURPOSE: To investigate the impact of race on the risk of pathological upgrading and upstaging at radical prostatectomy (RP) in an Asian (Korean) and Western (Caucasian) cohort eligible for active surveillance (AS). MATERIALS AND METHODS: We performed a retrospective cohort study of 854 patients eli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jeon, Hwang Gyun, Yoo, Jae Ho, Jeong, Byong Chang, Seo, Seong Il, Jeon, Seong Soo, Choi, Han-Yong, Lee, Hyun Moo, Ferrari, Michelle, Brooks, James D., Chung, Benjamin I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685613/ https://www.ncbi.nlm.nih.gov/pubmed/29136019 http://dx.doi.org/10.1371/journal.pone.0186026

Ejemplares similares

Predictive factors of unfavorable prostate cancer in patients who underwent prostatectomy but eligible for active surveillance
por: Choo, Seol Ho, et al.
Publicado: (2014)

The presence of primary circulating prostate cells is associated with upgrading and upstaging in patients eligible for active surveillance
por: Murray, Nigel P, et al.
Publicado: (2017)

Upgrading and upstaging of low-risk prostate cancer among Korean patients: a multicenter study
por: Hwang, Insang, et al.
Publicado: (2015)

Mutation of MED12 is not a frequent occurrence in prostate cancer of Korean patients
por: Yoon, Nara, et al.
Publicado: (2017)

Comparison of Pathological and Biochemical Outcomes after Radical Prostatectomy in Korean Patients with Serum PSA Ranges
por: Lee, Hye Won, et al.
Publicado: (2015)

Genomic analysis of Korean patients with advanced prostate cancer by use of a comprehensive next-generation sequencing panel and low-coverage, whole-genome sequencing
por: Kang, Minyong, et al.
Publicado: (2019)

The clinical utility of transperineal template-guided saturation prostate biopsy for risk stratification after transrectal ultrasound-guided biopsy
por: Song, Wan, et al.
Publicado: (2019)

Detection of prostate cancer using prostate imaging reporting and data system score and prostate-specific antigen density in biopsy-naive and prior biopsy-negative patients
por: Ryoo, Hyunsoo, et al.
Publicado: (2020)

Correlation between Gleason score distribution and Prostate Health Index in patients with prostate-specific antigen values of 2.5–10 ng/mL
por: Choi, Joongwon, et al.
Publicado: (2020)

Is Radical Perineal Prostatectomy a Viable Therapeutic Option for Intermediate- and High-risk Prostate Cancer?
por: Lee, Hye Won, et al.
Publicado: (2015)

Comparison of Prostate-Specific Antigen and Its Density and Prostate Health Index and Its Density for Detection of Prostate Cancer
por: Boo, Youngjun, et al.
Publicado: (2023)

Genomic mutation profiling using liquid biopsy in Korean patients with prostate cancer: Circulating tumor DNA mutation predicts the development of castration resistance
por: Yu, Jiwoong, et al.
Publicado: (2021)

Urinary DNA methylation biomarkers for prediction of prostate cancer upgrading and upstaging
por: Bakavicius, Arnas, et al.
Publicado: (2019)

Adverse upgrading and/or upstaging in contemporary low-risk prostate cancer patients
por: Flammia, Rocco S., et al.
Publicado: (2022)

Interval from Prostate Biopsy to Radical Prostatectomy Does Not Affect Immediate Operative Outcomes for Open or Minimally Invasive Approach
por: Park, Bumsoo, et al.
Publicado: (2014)

Usefulness of MRI targeted prostate biopsy for detecting clinically significant prostate cancer in men with low prostate-specific antigen levels
por: Bang, Seokhwan, et al.
Publicado: (2021)

Strategy for Prostate Cancer Patients with Low Prostate Specific Antigen Level (2.5 to 4.0 ng/mL)
por: Chung, Jae Hoon, et al.
Publicado: (2020)

Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
por: Jin, Byung-Soo, et al.
Publicado: (2015)

The Impact of Prostate Cancer Upgrading and Upstaging on Biochemical Recurrence and Cancer-Specific Survival
por: Bakavičius, Arnas, et al.
Publicado: (2020)

The clinical usefulness of natural killer cell activity in patients with suspected or diagnosed prostate cancer: an observational cross-sectional study
por: Song, Wan, et al.
Publicado: (2018)

Risk factors for prostate-specific antigen persistence in pT3aN0 prostate cancer after robot-assisted laparoscopic radical prostatectomy: a retrospective study
por: Kim, Jun Seop, et al.
Publicado: (2023)

Combination of multiparametric magnetic resonance imaging and transperineal template-guided mapping prostate biopsy to determine potential candidates for focal therapy
por: Choi, Young Hyo, et al.
Publicado: (2023)

Clinical Utility of Prostate Health Index for Diagnosis of Prostate Cancer in Patients with PI-RADS 3 Lesions
por: Lee, Chung-Un, et al.
Publicado: (2022)

Low serum testosterone predicts upgrading and upstaging of prostate cancer after radical prostatectomy
por: Gao, Yuan, et al.
Publicado: (2016)

Pathological upgrading and upstaging at radical prostatectomy in Jamaican men with low-risk prostate cancer
por: Morrison, Belinda F, et al.
Publicado: (2019)

Assessment of Agreement between Two Difference Prostate-Specific Antigen Assay Modalities
por: Chung, Jae Hoon, et al.
Publicado: (2021)

Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value
por: Chung, Jae Hoon, et al.
Publicado: (2021)

Diagnostic and Prognostic Significance of Radiologic Node-positive Renal Cell Carcinoma in the Absence of Distant Metastases: A Retrospective Analysis of Patients Undergoing Nephrectomy and Lymph Node Dissection
por: Lee, Hye Won, et al.
Publicado: (2015)

Histological characteristics of the largest and secondary tumors in radical prostatectomy specimens and implications for focal therapy
por: Choi, Young Hyo, et al.
Publicado: (2019)

Immunohistochemical staining of ERG and SOX9 as potential biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer
por: Song, Wan, et al.
Publicado: (2016)

Prostate-specific antigen kinetics in hypofractionated radiation therapy alone for intermediate- and high-risk localized prostate cancer
por: Lee, Tae Hoon, et al.
Publicado: (2023)

Atezolizumab in Patients with Pretreated Urothelial Cancer: a Korean Single-Center, Retrospective Study
por: Hur, Joon Young, et al.
Publicado: (2019)

Outcome of Prostate Biopsy in Men Younger than 40 Years of Age with High Prostate-Specific Antigen (PSA) Levels
por: Yang, Jin Bak, et al.
Publicado: (2010)

Utility of multiple core biopsies during transperineal template-guided mapping biopsy for patients with large prostates and PI-RADS 1–2 on multiparametric magnetic resonance imaging
por: Lee, Chung Un, et al.
Publicado: (2022)

Correction: Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value
por: Chung, Jae Hoon, et al.
Publicado: (2022)

The Role of Prostate Combination Biopsy Consisting of Targeted and Additional Systematic Biopsy
por: Lee, Chung Un, et al.
Publicado: (2021)

A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer
por: Byeon, Seonggyu, et al.
Publicado: (2021)

Incidence and Predictive Factors of Benign Renal Lesions in Korean Patients with Preoperative Imaging Diagnoses of Renal Cell Carcinoma
por: Park, Seo Yong, et al.
Publicado: (2011)

Predictive Preoperative Factors for Renal Insufficiency in Patients Followed for More Than 5 Years After Radical Nephrectomy
por: Ahn, Joong Seo, et al.
Publicado: (2013)

ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT)
por: Choi, Jae Duck, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tu59a2l0mslm5p9hbialqitdc9